Capital Management Corp VA Has $9.48 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Capital Management Corp VA lifted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 7.5% in the third quarter, HoldingsChannel.com reports. The firm owned 365,270 shares of the biotechnology company’s stock after purchasing an additional 25,350 shares during the quarter. Exelixis comprises 1.7% of Capital Management Corp VA’s investment portfolio, making the stock its 26th largest position. Capital Management Corp VA’s holdings in Exelixis were worth $9,479,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. First Trust Direct Indexing L.P. bought a new stake in shares of Exelixis during the 1st quarter valued at $250,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Exelixis by 3.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company’s stock worth $778,000 after buying an additional 1,301 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Exelixis by 6.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company’s stock valued at $1,442,000 after acquiring an additional 3,510 shares during the last quarter. Nordea Investment Management AB raised its position in shares of Exelixis by 17.3% in the 1st quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company’s stock valued at $4,835,000 after acquiring an additional 29,784 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in Exelixis during the first quarter valued at approximately $1,281,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 0.5 %

Exelixis stock opened at $34.29 on Tuesday. The company has a market capitalization of $9.79 billion, a price-to-earnings ratio of 21.98, a PEG ratio of 0.92 and a beta of 0.51. The stock’s 50 day moving average is $27.13 and its 200-day moving average is $24.31. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $34.65.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. During the same quarter last year, the firm earned $0.10 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. As a group, equities research analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Christopher J. Senner sold 125,000 shares of the stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the sale, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 354,020 shares of company stock valued at $9,386,366 in the last quarter. Company insiders own 2.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. BMO Capital Markets increased their target price on shares of Exelixis from $29.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Oppenheimer reissued an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Bank of America increased their price target on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Finally, TD Cowen lifted their price target on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.